Canadian events cast shadow over Japan's H1N1 vaccine plans
This article was originally published in Scrip
Executive Summary
Japan's government is launching a probe into the higher than normal incidence of anaphylaxis reported for one lot of a GlaxoSmithKline H1N1 vaccine in Canada, and may, if necessary, modify its plans to import millions of doses of the product from the UK firm.